These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31911865)

  • 21. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer.
    Ballinger TJ; Meier JB; Jansen VM
    Front Oncol; 2018; 8():308. PubMed ID: 30148117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.
    Rocca A; Maltoni R; Bravaccini S; Donati C; Andreis D
    Cancer Manag Res; 2018; 10():3083-3099. PubMed ID: 30214302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers.
    Ngan RKC
    Ann Transl Med; 2018 Jul; 6(14):284. PubMed ID: 30105234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of ER positive metastatic breast cancer.
    McAndrew NP; Finn RS
    Semin Oncol; 2020 Oct; 47(5):270-277. PubMed ID: 32958261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
    Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
    Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
    Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
    Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
    Rugo HS; Vidula N; Ma C
    Am Soc Clin Oncol Educ Book; 2016; 35():e40-54. PubMed ID: 27249746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
    Nagaraj G; Ma C
    Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
    Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
    Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
    Perez EA
    Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer.
    Finnegan RM; Elshazly AM; Patel NH; Tyutyunyk-Massey L; Tran TH; Kumarasamy V; Knudsen ES; Gewirtz DA
    Front Oncol; 2022; 12():966441. PubMed ID: 36741704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.